Kiniksa Intangible Assets vs Current Deferred Revenue Analysis

KNSA Stock  USD 21.41  0.09  0.42%   
Kiniksa Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kiniksa Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kiniksa Pharmaceuticals is a good investment. Please check the relationship between Kiniksa Pharmaceuticals Intangible Assets and its Current Deferred Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.

Intangible Assets vs Current Deferred Revenue

Intangible Assets vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kiniksa Pharmaceuticals Intangible Assets account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong relationship.
The correlation between Kiniksa Pharmaceuticals' Intangible Assets and Current Deferred Revenue is 0.78. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Kiniksa Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kiniksa Pharmaceuticals' Intangible Assets and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of Kiniksa Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Intangible Assets i.e., Kiniksa Pharmaceuticals' Intangible Assets and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.78
Relationship DirectionPositive 
Relationship StrengthSignificant

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.
Most indicators from Kiniksa Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kiniksa Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.The current year's Selling General Administrative is expected to grow to about 125.9 M, whereas Tax Provision is forecasted to decline to (5.8 M).
 2021 2022 2023 2024 (projected)
Interest Income97K1.3M1.1M1.6M
Net Interest Income97K1.3M1.1M1.6M

Kiniksa Pharmaceuticals fundamental ratios Correlations

0.860.94-0.070.950.93-0.5-0.820.80.560.760.490.470.830.950.840.7-0.820.940.920.81-0.50.920.880.840.91
0.860.94-0.030.80.82-0.57-0.80.670.620.690.580.30.680.840.750.51-0.640.860.890.84-0.230.80.830.840.76
0.940.94-0.10.90.92-0.55-0.870.810.610.720.550.350.790.950.830.67-0.80.940.960.8-0.410.930.90.930.87
-0.07-0.03-0.10.02-0.160.180.310.05-0.130.39-0.71-0.39-0.29-0.26-0.22-0.250.36-0.27-0.12-0.230.41-0.160.08-0.19-0.23
0.950.80.90.020.92-0.5-0.850.770.570.80.460.370.850.930.820.74-0.860.910.890.77-0.610.960.940.780.92
0.930.820.92-0.160.92-0.42-0.910.660.480.610.560.220.880.980.880.78-0.890.970.960.81-0.610.950.890.870.93
-0.5-0.57-0.550.18-0.5-0.420.31-0.72-0.99-0.15-0.26-0.13-0.67-0.46-0.11-0.670.6-0.42-0.37-0.210.45-0.54-0.33-0.45-0.65
-0.82-0.8-0.870.31-0.85-0.910.31-0.5-0.38-0.63-0.78-0.35-0.76-0.94-0.94-0.60.83-0.95-0.93-0.890.58-0.91-0.91-0.81-0.81
0.80.670.810.050.770.66-0.72-0.50.740.590.130.380.690.710.450.68-0.690.660.660.37-0.40.760.640.720.75
0.560.620.61-0.130.570.48-0.99-0.380.740.240.280.140.710.520.170.7-0.640.470.440.27-0.480.60.410.490.69
0.760.690.720.390.80.61-0.15-0.630.590.240.230.450.390.640.720.24-0.430.660.710.69-0.130.660.860.540.51
0.490.580.55-0.710.460.56-0.26-0.780.130.280.230.490.490.660.720.29-0.60.70.620.8-0.450.550.510.490.51
0.470.30.35-0.390.370.22-0.13-0.350.380.140.450.490.190.390.460.05-0.280.410.290.47-0.130.30.290.260.27
0.830.680.79-0.290.850.88-0.67-0.760.690.710.390.490.190.870.630.97-0.920.830.760.59-0.770.910.710.770.99
0.950.840.95-0.260.930.98-0.46-0.940.710.520.640.660.390.870.910.74-0.911.00.970.85-0.620.960.90.870.93
0.840.750.83-0.220.820.88-0.11-0.940.450.170.720.720.460.630.910.44-0.730.940.930.94-0.450.830.890.750.72
0.70.510.67-0.250.740.78-0.67-0.60.680.70.240.290.050.970.740.44-0.850.680.620.36-0.760.820.560.70.92
-0.82-0.64-0.80.36-0.86-0.890.60.83-0.69-0.64-0.43-0.6-0.28-0.92-0.91-0.73-0.85-0.88-0.82-0.640.88-0.93-0.76-0.69-0.93
0.940.860.94-0.270.910.97-0.42-0.950.660.470.660.70.410.831.00.940.68-0.880.980.9-0.580.940.90.860.9
0.920.890.96-0.120.890.96-0.37-0.930.660.440.710.620.290.760.970.930.62-0.820.980.88-0.480.920.930.880.84
0.810.840.8-0.230.770.81-0.21-0.890.370.270.690.80.470.590.850.940.36-0.640.90.88-0.330.740.830.690.68
-0.5-0.23-0.410.41-0.61-0.610.450.58-0.4-0.48-0.13-0.45-0.13-0.77-0.62-0.45-0.760.88-0.58-0.48-0.33-0.68-0.47-0.3-0.71
0.920.80.93-0.160.960.95-0.54-0.910.760.60.660.550.30.910.960.830.82-0.930.940.920.74-0.680.920.860.95
0.880.830.90.080.940.89-0.33-0.910.640.410.860.510.290.710.90.890.56-0.760.90.930.83-0.470.920.770.79
0.840.840.93-0.190.780.87-0.45-0.810.720.490.540.490.260.770.870.750.7-0.690.860.880.69-0.30.860.770.83
0.910.760.87-0.230.920.93-0.65-0.810.750.690.510.510.270.990.930.720.92-0.930.90.840.68-0.710.950.790.83
Click cells to compare fundamentals

Kiniksa Pharmaceuticals Account Relationship Matchups

Kiniksa Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets254.5M349.5M232.8M459.7M526.3M309.2M
Other Current Liab25K27.1M36.2M32.6M50.6M27.0M
Total Current Liabilities27.8M31.8M44.8M47.1M63.7M38.2M
Total Stockholder Equity(356.1M)(517.5M)(675.4M)(492.0M)438.8M460.8M
Net Tangible Assets225.4M311.9M194.5M377.9M434.6M456.3M
Property Plant And Equipment Net8.3M10.6M8.4M7.0M12.7M7.4M
Net Debt(44.3M)(107.1M)(116.4M)(116.8M)(95.7M)(100.5M)
Retained Earnings(356.1M)(517.5M)(675.4M)(492.0M)(478.0M)(501.8M)
Accounts Payable5.7M503K1.9M7.9M8.2M5.0M
Cash46.9M114.0M122.5M122.7M108.0M126.9M
Non Current Assets Total12.9M16.2M36.4M216.6M250.0M262.5M
Non Currrent Assets Other210K5.6M8.7M5.8M827K785.7K
Other Assets4.6M12.2M8.7M191.3M1.00.95
Cash And Short Term Investments233.4M323.5M182.2M190.6M206.4M212.4M
Common Stock Total Equity13K15K18K19K21.9K13.4K
Common Stock Shares Outstanding54.0M61.8M68.6M70.4M71.9M57.9M
Short Term Investments186.5M209.4M59.7M67.9M98.4M117.9M
Liabilities And Stockholders Equity(327.0M)(479.9M)(627.6M)(428.5M)526.3M552.6M
Non Current Liabilities Total1.3M5.7M2.9M16.5M23.8M25.0M
Capital Surpluse581.5M829.4M860.5M888.1M1.0B571.2M
Other Current Assets8.2M9.8M13.2M10.5M17.5M9.3M
Other Stockholder Equity(48K)829.4M860.5M888.1M916.8M480.8M
Total Liab29.1M37.5M47.8M63.5M87.5M52.8M
Property Plant And Equipment Gross8.3M10.6M14.3M13.9M20.5M21.5M
Total Current Assets241.6M333.2M196.4M243.1M276.3M234.8M
Accumulated Other Comprehensive Income33K(34K)(66K)44K6K6.3K
Common Stock13K15K18K19K20K14.4K
Property Plant Equipment8.3M4.1M2.8M1.7M1.9M3.7M
Net Invested Capital225.4M311.9M185.0M396.1M438.8M274.5M
Net Working Capital213.8M301.4M151.6M196.0M212.6M216.3M
Other Liab326K805K270K13.8M15.9M16.7M
Retained Earnings Total Equity(356.1M)(517.5M)(675.4M)(492.0M)(442.8M)(465.0M)
Non Current Liabilities Other326K5.7M2.9M16.5M1.9M1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
5.5
Earnings Share
(0.12)
Revenue Per Share
5.415
Quarterly Revenue Growth
0.674
Return On Assets
(0.03)
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.